EyePoint Inc (EYPT.A): Adding Upside 90-Day Catalyst Watch

Research evidence excerpt

Action |

05 Aug 2026 06:16:53 ET │ 10 pages

EyePoint Inc (EYPT.A)

Adding Upside 90-Day Catalyst Watch

Direction:

Upside

Duration:

Within 90 Days

Catalyst:

Mgmt announcement

Buy / High Risk

Catalyst Watch: Upside

We are reopening our 90-day upside Catalyst Watch on EYPT given what

we believe is a highly favorable setup ahead of topline Ph3 data for

DURAVYU in wAMD expected likely in mid-to-late August for LUGANO,

Price (04 Aug 26 16:00)

US$11.78

Target price

US$35.00

Expected share price return

197.1%

Expected dividend yield

0.0%

Expected total return

197.1%

Market Cap

US$988M

followed by LUCIA ~8 weeks after. Given masked safety data continuing

to track in line with DURAVYU's prior four clinical trials, a ~6%

Yigal Nochomovitz, Ph.D.AC

discontinuation rate which is well below the ~10% annual average for

wAMD trials, and three consecutive positive DSMC recommendations, we

expect DURAVYU's safety profile to remain clean/consistent with DAVIO

2 and meaningfully differentiated vs. AXPAXLI's profile in SOL-1. On

efficacy, our base case assumes noninferiority on BCVA and a favorable

rescue rate, supported by the Ph3's tightened supplement criteria relative

Joohwan Kim

Caroline DePaul

to Ph2. We believe a favorable LUGANO readout could be a significant rerating event from current levels given the readout represents EYPT’s most

significant inflection point to date.

EPS (US$)

Q1

Q2

Q3

Q4

FY

FC Cons

VA Cons

2025A

-0.65A

-0.85A

-0.81A

-3.17A

2026E

-0.99A

-1.00E

-1.03E

-1.05E

-4.06E

-3.56E

-3.79E

Previous

-0.99A

-1.00E

-1.03E

-1.05E

-4.06E

na

2027E

na

-3.62E

-3.10E

-3.54E

Previous

na

-3.62E

na

2028E

na

-0.65E

-1.60E

-1.47E

Previous

na

-0.65E

na

Source: Company Reports and dataCentral, Citi Research. FC Cons: First Call Consensus. VA Cons: Visible Alpha Consensus.

Click here for Visible Alpha consensus data